Page 898 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPtEr 63 Bullous Diseases of the Skin and Mucous Membranes 869

2. Joly P, Litrowski N. Pemphigus group (vulgaris, vegetans, foliaceus, 27. Chen YJ, Wu CY, Lin MW, et al. Comorbidity profiles among patients
herpetiformis, brasiliensis). Clin Dermatol 2011;29:432–6. with bullous pemphigoid: a nationwide population-based study. Br J
3. Bolognia JL, Jean L, Jorizzo JL, et al. Pemphigus. In: Bologina JL, Jean L, Dermatol 2011;165:593–9.
Jorizzo JL, et al, editors. Dermatology. Cambridge, UK: Elsevier Health 28. Giudice GJ, Emery DJ, Zelickson BD, et al. Bullous pemphigoid and
Sciences; 2012. 29 p. 461–74. herpes gestationis autoantibodies recognize a common non-collagenous
4. Risser J, Lewis K, Weinstock MA. Mortality of bullous skin disorders from site on the BP180 ectodomain. J Immunol 1993;151:5742–50.
1979 through 2002 in the United States. Arch Dermatol 2009;145:1005–8. 29. McGrath JA, Darling T, Gatalica B, et al. A homozygous deletion
5. Beutner EH, Jordon RE. Demonstration of skin antibodies in the sera of mutation in the gene encoding the 180-kDa bullous pemphigoid antigen
pemphigus vulgaris patients by indirect immunofluorescent staining. (BPAG2) in a family with generalized atrophic benign epidermolysis
Proc Soc Exp Biol Med 1964;117:505–10. bullosa. J Invest Dermatol 1996;106:771–4.
6. Aoki V, Sousa JX Jr, Diaz LA, et al. Pathogenesis of endemic pemphigus 30. Messingham KA, Holahan HM, Fairley JA. Unraveling the significance of
foliaceus. Dermatol Clin 2011;29:413–18, viii. IgE autoantibodies in organ-specific autoimmunity: lessons learned from
7. Maruani A, Machet MC, Carlotti A, et al. Immunostaining with antibodies bullous pemphigoid. Immunol Res 2014;59:273–8.
to desmoglein provides the diagnosis of drug-induced pemphigus and 31. Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous
allows prediction of outcome. Am J Clin Pathol 2008;130:369–74. pemphigoid. Cochrane Database Syst Rev 2010;(10):CD002292.
8. Anhalt GJ. Paraneoplastic pemphigus. J Investig Dermatol Symp Proc 32. Beissert S, Werfel T, Frieling U, et al. A comparison of oral
2004;9:29–33. methylprednisolone plus azathioprine or mycophenolate mofetil for the
9. Düker I, Schaller J, Rose C, et al. Subcorneal pustular dermatosis-type IgA treatment of bullous pemphigoid. Arch Dermatol 2007;143:1536–42.
pemphigus with autoantibodies to desmocollins 1, 2, and 3. Arch 33. Peterson JD, Chan LS. Effectiveness and side effects of anti-CD20 therapy
Dermatol 2009;145:1159–62. for autoantibody-mediated blistering skin diseases: a comprehensive
10. Ishii K, Amagai M, Hall RP, et al. Characterization in pemphigus using survey of 71 consecutive patients from the initial use to 2007. Ther Clin
antigen-specific enzyme-linked immunosorbent assays with baculovirus- Risk Manag 2009;5:1–7.
expressed recombinant desmogleins. J Immunol 1997;159:2010–17. 34. Yu KK, Crew AB, Messingham KA, et al. Omalizumab therapy for bullous
11. Anhalt GJ, Labib RS, Voorhees JJ, et al. Induction of pemphigus in pemphigoid. J Am Acad Dermatol 2014;71:468–74.
neonatal mice by passive transfer of IgG from patients with the disease. N 35. Ishii N, Hamada T, Dainichi T, et al. Epidermolysis bullosa acquisita:
Engl J Med 1982;306:1189–96. what’s new? J Dermatol 2010;37:220–30.
12. Aoki V, Rivitti EA, Diaz LA, et al. Update on fogo selvagem, an endemic 36. Gammon WR, Heise ER, Burke WA, et al. Increased frequency of
form of pemphigus foliaceus. J Dermatol 2015;42:18–26. HLA-DR2 in patients with autoantibodies to epidermolysis bullosa
13. Warren SJ, Lin MS, Giudice GJ, et al. The prevalence of antibodies against acquisita antigen: evidence that the expression of autoimmunity to type
desmoglein 1 in endemic pemphigus foliaceus in Brazil. Cooperative VII collagen is HLA class II allele associated. J Invest Dermatol
Group on Fogo Selvagem Research. N Engl J Med 2000;343:23–30. 1988;91:228–32.
14. Diaz LA, Prisayanh PS, Dasher DA, et al. The IgM anti-desmoglein 1 37. Ludwig RJ, Recke A, Bieber K, et al. Generation of antibodies of distinct
response distinguishes Brazilian pemphigus foliaceus (fogo selvagem) subclasses and specificity is linked to H2s in an active mouse model of
from other forms of pemphigus. J Invest Dermatol 2008;128:667–75. epidermolysis bullosa acquisita. J Invest Dermatol 2011;131:167–76.
15. Warren SJ, Arteaga LA, Rivitti EA, et al. The role of subclass switching in 38. Srinivas G, Moller S, Wang J, et al. Genome-wide mapping of
the pathogenesis of endemic pemphigus foliaceus. J Invest Dermatol gene-microbiota interactions in susceptibility to autoimmune skin
2003;120:104–8. blistering. Nat Commun 2013;4:2462.
16. Qian Y, Jeong JS, Ye J, et al. Overlapping IgG4 responses to self- and 39. Tukaj S, Zillikens D, Kasperkiewicz M. Inhibitory effects of heat shock
environmental antigens in endemic pemphigus foliaceus. J Immunol protein 90 blockade on proinflammatory human Th1 and Th17 cell
2016;196:2041–50. subpopulations. J Inflamm (Lond) 2014;11:10.
17. Malhoney MG, Wang ZH, Stanley JR. Pemphigus vulgaris and pemphigus 40. Chi CC, Wang SH, Charles-Holmes R, et al. Pemphigoid gestationis: early
foliaceus antibodies are pathogenic in plasminogen activator knockout onset and blister formation are associated with adverse pregnancy
mice. J Invest Dermatol 1999;113:22–5. outcomes. Br J Dermatol 2009;160:1222–8.
18. Berkowitz P, Hu P, Warren S, et al. p38MAPK inhibition prevents disease 41. Shornick JK, Artlett CM, Jenkins RE, et al. Complement polymorphism
in pemphigus vulgaris mice. Proc Natl Acad Sci USA 2006;103:12855–60. in herpes gestationis: association with C4 null allele. J Am Acad Dermatol
19. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized 1993;29:545–9.
controlled open-label trial of four treatment regimens for pemphigus 42. Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus
vulgaris. J Am Acad Dermatol 2007;57:622–8. on mucous membrane pemphigoid: definition, diagnostic criteria,
20. Beissert S, Mimouni D, Kanwar AJ, et al. Treating pemphigus vulgaris pathogenic factors, medical treatment, and prognostic indicators. Arch
with prednisone and mycophenolate mofetil: a multicenter, randomized, Dermatol 2002;138:370–9.
placebo-controlled trial. J Invest Dermatol 2010;130:2041–8. 43. Yasukochi A, Teye K, Ishii N, et al. Clinical and immunological study
21. Hall RP 3rd, Fairley J, Woodley D, et al. A multicentre randomized trial of 332 Japanese patients tentatively diagnosed with anti-BP180-type
of the treatment of patients with pemphigus vulgaris with infliximab and mucous membrane pemphigoid: a novel BP180 C-terminal domain
prednisone compared with prednisone alone. Br J Dermatol enzyme-linked immunosorbent assay. Acta Derm Venereol 2016;96:
2015;172:760–8. 762–7.
22. Amagai M, Ikeda S, Shimizu H, et al. A randomized double-blind trial of 44. Chan LS, Yancey KB, Hammerberg C, et al. Immune-mediated
intravenous immunoglobulin for pemphigus. J Am Acad Dermatol subepithelial blistering diseases of mucous membranes: pure ocular
2009;60:595–603. cicatricial pemphigoid is a unique clinical and immunopathological
23. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the entity distinct from bullous pemphigoid and other subsets identified by
treatment of severe pemphigus. N Engl J Med 2007;357:545–52. antigenic specificity of autoantibodies. Arch Dermatol 1993;129:448–55.
24. Colliou N, Picard D, Caillot F, et al. Long-term remissions of severe 45. Egan CA, Lazarova Z, Darling TN, et al. Anti-epiligrin cicatricial
pemphigus after rituximab therapy are associated with prolonged failure pemphigoid: clinical findings, immunopathogenesis, and significant
of desmoglein B cell response. Sci Transl Med 2013;5:175ra130. associations. Medicine (Baltimore) 2003;82:177–86.
25. Jedlickova H, Hlubinka M, Pavlik T, et al. Bullous pemphigoid and 46. Shipman AR, Ali I, Murrell DF, et al. Mucous membrane pemphigoid: are
internal diseases—a case-control study. Eur J Dermatol 2010;20: laminin 5 antibodies a risk factor for laryngeal involvement? J Eur Acad
96–101. Dermatol Venereol 2009;23:169–70.
26. Liu JJ, Ding J, Kowal AS, et al. BPAG1n4 is essential for retrograde axonal 46a. Setterfield J, Theron J, Vaughan RW, et al. Mucous membrane
transport in sensory neurons. J Cell Biol 2003;163:223–9. pemphigoid: HLADQB1* 0301 is associated with all clinical sites of